PrabotulinumtoxinA for the treatment of glabellar lines in adults, 65 years of age and older: The fourth in a series of post hoc analyses of the phase III clinical study data
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Cosmetic Dermatology"
DOI: 10.1111/jocd.15783
Abstract: Despite the absence of Phase III clinical trial data to support their use, 3.4% of all neurotoxin treatments performed internationally for esthetic purposes in 2020 were performed in patients 65 years of age and older. read more here.
Keywords: age older; phase iii; iii clinical; years age ... See more keywords
Changes in key recruitment performance metrics from 2008–2019 in industry-sponsored phase III clinical trials registered at ClinicalTrials.gov
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0271819
Abstract: Background Increasing costs and complexity in clinical trials requires recruitment of more narrowly defined patient populations. However, recruitment for clinical trials remains a considerable challenge. Aim Our overall aim was to quantify recruitment performance in… read more here.
Keywords: industry sponsored; clinical trials; number; iii clinical ... See more keywords
Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.719623
Abstract: The most common primary intracranial tumor is glioma, among which glioblastoma (GBM) has the worst prognosis. Because of the high degree of malignancy of GBM and frequent recurrence after surgery, postoperative therapy, including chemotherapy, radiotherapy,… read more here.
Keywords: phase; imposing phase; clinical trials; phase iii ... See more keywords
Tumour Burden Reporting in Phase III Clinical Trials of Metastatic Lung, Breast, and Colorectal Cancers: A Systematic Review
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14133262
Abstract: Simple Summary The initial tumour burden is a strong and well-known prognostic factor in oncology. A systematic review was performed to examine if and how the initial tumour burden is reported in phase III clinical… read more here.
Keywords: clinical trials; disease; iii clinical; tumour burden ... See more keywords